Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib
ConclusionsThis is the first case in literature about activity of dasatinib in combination with a chemotherapy schedule of oral vinorelbine and capecitabine in advanced breast cancer. This treatment showed both good tolerability and great activity with a long progression free survival of 54 months.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | CT Scan | Hematology | Hormones | Leukemia | Liver | Oral Cancer | PET Scan | Study | Urology & Nephrology | Xeloda